Major ophthalmic events in the first quarter of 2026 included treatments for presbyopia, age-related macular degeneration ...

The TECNIS PureSee IOL addresses both cataract-related vision loss and presbyopia, which affects near vision as eyes age.

Please provide your email address to receive an email when new articles are posted on . The extended depth of focus IOL has no warning on loss of contrast sensitivity. The lens will be available in ...

JACKSONVILLE, Fla., March 12, 2026--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) announced U.S. Food and Drug Administration (FDA) approval of TECNIS PureSee IOL, an extended depth of focus (EDOF) ...

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Johnson & Johnson (NYSE:JNJ) received FDA approval for its ...

Johnson & Johnson (JNJ) announced on Thursday that the U.S. Food and Drug Administration (FDA) approved its Tecnis PureSee intraocular lens (IOL), giving eye surgeons a new lens option for use in ...

FDA has approved Johnson & Johnson's Tecnis PureSee IOL, an extended depth of focus (EDOF) intraocular lens (IOL) intended for use in cataract surgery. The new IOL will be available to U.S. patients ...

Add Yahoo as a preferred source to see more of our stories on Google. The approval adds to J&J’s surgical vision portfolio Johnson & Johnson (J&J) has received approval from the US Food and Drug ...

Johnson & Johnson (NYSE: JNJ) announced U.S. Food and Drug Administration (FDA) approval of TECNIS PureSee IOL, an extended depth of focus (EDOF) intraocular lens (IOL) intended for use in cataract ...